August 6, 2014
Management of the National Nuclear Security Administration’s Biosafety Laboratories
To conduct biological research, the Department of Energy (Department) and the National Nuclear Security Administration (NNSA) operate multiple laboratory facilities in accordance with various biosafety levels (BSL) established by the Centers for Disease Control and Prevention. The BSLs classify the containment level and risk associated with biological agents depending on the threat the agents pose to personnel and the environment. For example, BSL-1 is for low-risk agents; BSL-2 is for medium-risk agents; and BSL-3 is for those agents that cause serious and potentially lethal infections. Department and NNSA sites primarily perform BSL-1 and BSL-2 research; however, Lawrence Livermore National Laboratory (LLNL) operates a facility with three BSL-3 laboratories while Los Alamos National Laboratory (LANL) is considering opening a facility with two BSL-3 laboratories. Extensive biological research is performed at LLNL and LANL for other Government agencies through the Department's Work for Others (WFO) program.
We found that NNSA was considering a $9.5 million expansion of its BSL-3 and BSL-2 laboratory capabilities at LANL that may not be the most effective use of resources. Specifically, NNSA identified the development of a BSL-3 facility at LANL as its preferred alternative for meeting biosafety laboratory needs even though it had not fully considered the need for and cost effectiveness of additional capacity. Despite the lack of information on the need for additional capacity and current laboratory utilization rates, LANL was also considering building a new BSL-2 facility.
In particular, NNSA proposed development of a facility with two BSL-3 laboratories at LANL. Additionally, LANL is in the early planning stage for constructing a new BSL-2 facility. The estimated cost to open LANL's new BSL-3 and to construct/open BSL-2 capabilities was about $1.5 million and $8 million, respectively. Given current budget realities, plans to develop additional capabilities without fully demonstrating a need may not be prudent. We made several recommendations to help ensure biosafety laboratories and costs associated WFO activities are managed effectively.
Topic: Management & Administration